EFFICACY &
SAFETY

Helps relieve multiple occasional stomach upsets†
and demonstrated to be safe and well tolerated 1,2,*

 

EFFICACY &
SAFETY

Helps relieve multiple occasional stomach upsets† and demonstrated to be safe and well tolerated 1,2,*

 

 

 

 

 

 

 

 

 

 

EFFECTIVE AT HELPING RELIEVE OCCASIONAL
STOMACH UPSETS:1,2,†, *

IB-Yellow-Check-Mark

 INDIGESTION

IB-Yellow-Check-Mark

 BLOATING

IB-Yellow-Check-Mark

 ABDOMINAL  DISCOMFORT +           
    CONSTIPATION/DIARRHEA

IB-Yellow-Check-Mark

 HEARTBURN

IB-Yellow-Check-Mark

 NAUSEA

IB-Yellow-Check-Mark

 GAS

 

 

EFFECTIVE AT HELPING RELIEVE OCCASIONAL STOMACH UPSETS:1,2,†,*

IB-Yellow-Check-Mark

INDIGESTION

IB-Yellow-Check-Mark

BLOATING

IB-Yellow-Check-Mark

ABDOMINAL
DISCOMFORT +
CONSTIPATION/
DIARRHEA

IB-Yellow-Check-Mark

HEARTBURN

IB-Yellow-Check-Mark

NAUSEA

IB-Yellow-Check-Mark

GAS

IBEROGAST™ IS SUPPORTED BY A GROWING BODY OF CLINICAL EVIDENCE SPANNING DECADES

The efficacy and safety of Iberogast™️ in helping relieve occasional stomach upsets† has been shown in multiple studies over 3 decades, as well as a meta-analysis1,*

Timeline-Desktop
Timeline-Mobile

IBEROGAST™ PROVIDES CLINICALLY PROVEN DIGESTIVE RELIEF1,*

HELPS RELIEVE OCCASIONAL STOMACH UPSETS1,†,*

Clinically proven to deliver a statistically significant improvement in overall symptoms after 28 and 56 days of use.*

Subject data-based meta-analysis applying the latest guidelines

28-day_Improvement_desktop
28-day_Improvement_Mobile
56-day_Improvement_desktop
56-day_Improvement_Mobile

Improvement in overall symptoms vs baseline

Overall-Improvement_desktop
Overall-Improvement_Mobile

Study design

Meta-analysis of randomized, controlled, clinical studies testing IberogastTM, including data from patients with at least 1 of the following key symptoms at baseline: fullness, early satiety, or epigastric discomfort. Four randomized, controlled trials (including 613 patients) were identified, with 2 eligible for efficacy analysis: Madisch 2004 and Vinson 2020.

IBEROGAST™ IS DEMONSTRATED TO BE SAFE AND WELL TOLERATED

tolerability-table_desktop
tolerability-table_mobile
icon-correct

The tolerability and safety of IberogastTM  have been shown in multiple randomized, placebo-controlled clinical studies1,3,4,7

icon-correct

The safety profile of IberogastTM  is comparable to placebo1

   READ THE 2024 META-ANALYSIS   

RECOMMEND IBEROGAST™

Free patient coupons
and samples

Free patient coupons and samples

ORDER NOW

QUESTIONS ABOUT IBEROGAST™?

We’ve got answers

We’ve got answers

 

VISIT OUR FAQ

AE, adverse event; CI, confidence interval; GI, gastrointestinal.

†Helps relieve occasional: Indigestion, Bloating, Heartburn, Nausea, Gas, Abdominal Discomfort + Constipation/Diarrhea.*

‡This trial was published as an abstract and is not available online.

*This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

Click to expand.

    References

    References: 1. Andresen V, Shah A, Fink C, Rabini S, Wargenau M, Holtmann G. Digestion. 2024;105(3):166-174. doi:10.1159/000535672 2. Data on file, Bayer HealthCare. 3. Vinson B, Fink C, Wargenau M, Talley NJ, Holtmann G. JGH Open. 2024;8(5):e13054. doi:10.1002/jgh3.13054 4. Madisch A, Holtmann G, Mayr G, Vinson B, Hotz J. Digestion. 2004;69(1):45-52. doi:10.1159/000076546 5. Madisch A, Holtmann G, Plein K, Hotz J. Aliment Pharmacol Ther. 2004;19(3):271-279. doi:10.1111/j.1365-2036.2004.01859.x 6. Rösch W, Vinson B, Sassin I. Z Gastroenterol. 2002;40(6):401-408. doi:10.1055/s-2002-32130 7. Buchert D. Z Phytotherapie. 1994;15(1):45-46.

    Image